These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27275478)

  • 81. Options for the treatment of gemcitabine-resistant advanced pancreatic cancer.
    Gounaris I; Zaki K; Corrie P
    JOP; 2010 Mar; 11(2):113-23. PubMed ID: 20208317
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Targeted therapy for breast cancer: An overview of drug classes and outcomes.
    Jacobs AT; Martinez Castaneda-Cruz D; Rose MM; Connelly L
    Biochem Pharmacol; 2022 Oct; 204():115209. PubMed ID: 35973582
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Current State of "Omics" Biomarkers in Pancreatic Cancer.
    Turanli B; Yildirim E; Gulfidan G; Arga KY; Sinha R
    J Pers Med; 2021 Feb; 11(2):. PubMed ID: 33672926
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Masitinib in treatment of pancreatic cancer.
    Waheed A; Purvey S; Saif MW
    Expert Opin Pharmacother; 2018 May; 19(7):759-764. PubMed ID: 29638149
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Therapeutic Aspects and Molecular Targets of Autophagy to Control Pancreatic Cancer Management.
    Rahman MA; Ahmed KR; Rahman MDH; Parvez MAK; Lee IS; Kim B
    Biomedicines; 2022 Jun; 10(6):. PubMed ID: 35740481
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Current Pathology Model of Pancreatic Cancer.
    Szymoński K; Milian-Ciesielska K; Lipiec E; Adamek D
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565450
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Molecular biology of pancreatic neuroendocrine tumors: From mechanism to translation.
    Shen X; Wang X; Lu X; Zhao Y; Guan W
    Front Oncol; 2022; 12():967071. PubMed ID: 36248960
    [TBL] [Abstract][Full Text] [Related]  

  • 88. The RON receptor tyrosine kinase in pancreatic cancer pathogenesis and its potential implications for future targeted therapies.
    Kang CM; Babicky ML; Lowy AM
    Pancreas; 2014 Mar; 43(2):183-9. PubMed ID: 24518495
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Research progress on microRNAs as molecular markers in pancreatic cancer: a narrative review.
    Fu RB; Chen X; Chen Y; Ye QH; Yang B; Shao Q; Zhu JH
    J Gastrointest Oncol; 2022 Aug; 13(4):2048-2056. PubMed ID: 36092335
    [TBL] [Abstract][Full Text] [Related]  

  • 90. An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs).
    Alonso-Gordoa T; Díez JJ; Molina J; Reguera P; Martínez-Sáez O; Grande E
    Rare Cancers Ther; 2015; 3(1):13-33. PubMed ID: 27182476
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Clinical characteristics of pancreatic and biliary tract cancers in Lynch syndrome: A retrospective analysis from the Finnish National Lynch Syndrome Research Registry.
    Zalevskaja K; Mecklin JP; Seppälä TT
    Front Oncol; 2023; 13():1123901. PubMed ID: 36816932
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Molecular pathology of pancreatic cancer: from bench-to-bedside translation.
    Corbo V; Tortora G; Scarpa A
    Curr Drug Targets; 2012 Jun; 13(6):744-52. PubMed ID: 22458520
    [TBL] [Abstract][Full Text] [Related]  

  • 93. [Practice and challenge of precision medicine for pancreatic cancer].
    Shi XH; Jin G
    Zhonghua Wai Ke Za Zhi; 2020 Jan; 58(1):37-41. PubMed ID: 31902168
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Future directions in drug development in pancreatic cancer.
    Lambert A; Conroy T; Ducreux M
    Semin Oncol; 2021 Feb; 48(1):47-56. PubMed ID: 33674067
    [TBL] [Abstract][Full Text] [Related]  

  • 95. An update on treatment options for pancreatic adenocarcinoma.
    Lambert A; Schwarz L; Borbath I; Henry A; Van Laethem JL; Malka D; Ducreux M; Conroy T
    Ther Adv Med Oncol; 2019; 11():1758835919875568. PubMed ID: 31598142
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma.
    Rebelo R; Polónia B; Santos LL; Vasconcelos MH; Xavier CPR
    Pharmaceuticals (Basel); 2021 Mar; 14(3):. PubMed ID: 33804613
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Activation of the PI3K/AKT signaling pathway by ARNTL2 enhances cellular glycolysis and sensitizes pancreatic adenocarcinoma to erlotinib.
    Ge W; Wang Y; Quan M; Mao T; Bischof EY; Xu H; Zhang X; Li S; Yue M; Ma J; Yang H; Wang L; Yu Z; Wang L; Cui J
    Mol Cancer; 2024 Mar; 23(1):48. PubMed ID: 38459558
    [TBL] [Abstract][Full Text] [Related]  

  • 98. A Quest for Survival: A Review of the Early Biomarkers of Pancreatic Cancer and the Most Effective Approaches at Present.
    Bestari MB; Joewono IR; Syam AF
    Biomolecules; 2024 Mar; 14(3):. PubMed ID: 38540782
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Metastasis of pancreatic tumors].
    Häberle L; Braren R; Schlitter AM; Esposito I
    Pathologe; 2015 Nov; 36 Suppl 2():176-80. PubMed ID: 26391249
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Beware the Medical-Industrial Complex.
    Stevens CW; Glatstein E
    Oncologist; 1996; 1(4):IV-V. PubMed ID: 10388005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.